Business Wire

Intertrust Expands ExpressPlay Platform to Provide Seamless DRM Interoperability, Conditional Access, Audience Analytics, and Targeted Advertising

Jaa

Intertrust Technologies Corporation today announced a major expansion of Intertrust ExpressPlay™, its cloud platform that provides content distributors, network operators, and broadcasters with a single service that satisfies all their media monetization requirements in a highly cost-effective and efficient way. The platform is the first of its kind to combine content protection and management with audience understanding and targeted advertising to offer greater convenience, security, privacy and risk management in a single solution.

Traditionally, companies distributing Internet video procured these services from two or more vendors, creating risk, additional cost, and confusion. ExpressPlay provides convenience at a significantly lower price, and is built on years of R&D embodied in Intertrust’s seminal patent portfolio.

Intertrust expands its traditional ExpressPlay DRM platform, which to date is the only cloud-based platform that supports all major DRM formats. In a major leap forward in DRM systems, ExpressPlay introduces a new Universal DRM SDK that promises to end cross-device DRM format conflicts decisively. Service providers building applications with the ExpressPlay Universal SDK can use all major DRMs without custom integration for each one. The Universal DRM SDK also supports DASH CENC to native FairPlay, and offers the protected (DRM) DASH stack for iOS, which doesn’t exist natively. This means that service providers can reduce multiple asset formats, streamline their workflows and deliver premium content using the native DRM.

The new platform also uses the Intertrust Personagraph™ consumer data platform to provide server-side and client-side advertising, and audience understanding. A network operator or broadcaster can now use ExpressPlay to deploy and manage content in a common secure format, provide targeted ads using their own infrastructure and run analytics on their users’ data securely and privately without dependencies on competitors.

Intertrust ExpressPlay now includes,

  • ExpressPlay Universal DRM™ (uDRM): Intertrust’s leading multi-DRM platform that supports Adobe Access, Apple FairPlay, Google Widevine, Marlin DRM, and Microsoft PlayReady. The new Universal DRM (uDRM) SDK helps reduce costs by eliminating the need to distribute multiple versions of protected assets. It overcomes the challenges of the diverse device landscape (flavors of Android, iOS, etc), and efficiently implements offline playback of content on mobile devices. uDRM minimizes the need for complex backend systems and professional services.
  • ExpressPlay CA™: A new Marlin-based Conditional Access System (CAS) that allows broadcasters and network operators to deliver card-free, powerful CAS capabilities using the same Marlin DRM engine used for broadband DRM. One engine supports two security models and results in substantial savings over traditional limited CAS.
  • ExpressPlay Audience™: An advanced customer data platform that leverages Intertrust’s multi-billion user Personagraph consumer data platform. Audience provides understanding, advanced analytics, device graphs, and retail and marketing technology functions in a private and secure manner.
  • ExpressPlay Ads™: A custom white-label advertising platform that uses ExpressPlay Audience to insert personalized ads into protected content streams on mobile, TV, and web platforms. The platform supports both server-side and client-side ad insertion technology to reach a broad range of devices in a highly scalable and efficient manner.

This is the first platform of its kind that provides convenience, security, privacy, and risk management. The components can be used jointly as a complete system or separately.

Intertrust will showcase ExpressPlay and related partner demos at IBC 2017 at the RAI in Amsterdam in Hall 5, Booth 15 between September 15-19, 2017.

About Intertrust Technologies Corporation

Intertrust provides trusted computing products and services to leading global corporations – from mobile and CE manufacturers and service providers to enterprise software platform companies. These products include the world’s leading digital rights management, software tamper resistance and privacy-driven data platforms for digital advertising, marketing technologies, DNA analysis, and IoT.

Founded in 1990, Intertrust is based in Silicon Valley, with regional offices in London, Tokyo, Seoul and Beijing. The Company has a legacy of invention, and its fundamental contributions in the areas of computer security and digital trust are globally recognized. Intertrust holds hundreds of patents that are key to Internet security, trust, and privacy management components of operating systems, trusted mobile code and networked operating environments, web services, and cloud computing. Additional information is available at intertrust.com, or follow us on Twitter or LinkedIn.

Contact information

Actual Agency
Brian Regan (for Intertrust), 908-399-7161
brian.regan@actual.agency

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ipsen Receives Approval from European Commission for Xermelo® (Telotristat Ethyl) for the Treatment of Carcinoid Syndrome Diarrhea in Patients Inadequately Controlled by Somatostatin Analogue Therapy19.9.2017 19:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced that the European Commission has approved Xermelo® (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of Xermelo® (telotristat ethyl) in the above indication in all 28 member states of the European Union, Norway and Iceland. David Meek, Chief Executive Officer, Ipsen stated: “We are delighted to provide patients suffering from inadequately controlled carcinoid syndrome with a new treatment option in combination with a somatostatin analogue that demonstrates both efficacy and safety in particularly improving diarrhea, a most debilitating symptom. Xe

6th Annual World Patient Safety, Science & Technology Summit to Be Held in London, England19.9.2017 18:00Tiedote

The Patient Safety Movement Foundation (PSMF) announces that the 6th Annual World Patient Safety, Science & Technology Summit will take place in London on February 23-25, 2018. Rt. Hon. Jeremy Hunt MP, the Secretary of State for Health from England’s Department of Health, invited PSMF to hold its 6th annual Summit in London during his speech at the Summit in February of this year. This is the first time the Summit will be held outside of the United States. Over the years, the PSMF has taken an increasingly international scope to reach zero preventable patient deaths by 2020. They currently have over 30 Regional Chapters around the world and partnerships with global organizations such as the World Federation of Societies of Anaesthesiologists (WFSA), European Society of Anaesthesiology (ESA), Global Sepsis Alliance (GSA), the Taiwan Patient Safety Culture Club, Sistema Españo

Vertex Announces Upcoming Presentations of Data at 2017 North American Cystic Fibrosis Conference19.9.2017 17:50Tiedote

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that 11 abstracts from its cystic fibrosis (CF) research and development program will be presented at the annual North American Cystic Fibrosis Conference (NACFC) in Indianapolis, November 2 to 4, 2017. Previously announced data from the Phase 3 EVOLVE and EXPAND studies of the investigational tezacaftor/ivacaftor combination in people with CF ages 12 and older who have certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene will be presented for the first time. Additionally, data from the Phase 3 extension study of ORKAMBI® (lumacaftor/ivacaftor) in children with CF ages 6 to 11 who have two copies of the F508del mutation and real-world KALYDECO® (ivacaftor) data will be presented. The company also submitted an abstract for the late-breaking poster session with previously announced Phase 1

Biker Summer 2017 campaign: Last Chance to Win Great Prizes from Moto-tyres.co.uk19.9.2017 16:57Tiedote

Moto-tyres.co.uk wants to know: For the fifth year in a row, the online motorbike shop is asking bikers from ten European countries about their Biker Summer 2017 travel plans, favourite destinations and longest tours. For survey participants, Moto-tyres.co.uk and its sister shops in other European countries are raffling prizes to get every biker’s heart beating faster, including vouchers for new motorbike tyres, a GARMIN motorbike GPS navigation system, and a GoPro camera with helmet attachment. For more information and a link to the survey, go to: www.moto-tyres.co.uk/promotion-biker-summer-2017.html. The Biker Summer 2017 campaign is running until 30th September 2017 – so you still have time to join in and win top-quality equipment for your next bike tour. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170919006105/en/

Andersen Global Expands into Uruguay19.9.2017 16:30Tiedote

Andersen Global announces its expansion into Uruguay through a Collaboration Agreement with Fischer & Schickendantz, one of the country’s leading law firms. The addition of Fischer & Schickendantz continues Andersen Global’s expansion and robust presence within the Latin American region. The team is led by Managing Partner, Juan Federico Fischer. “The addition of Juan Federico and the individuals at Fischer & Schickendantz bring a new depth to our team and our business development efforts in South America, while allowing us to deliver additional services in the region,” said Andersen Tax CEO, Mark Vorsatz. “Uruguay is the next major step in our firm’s growth and is an excellent complement for Andersen Global. The ability to provide a full scope of services in Uruguay offers significant advantages, especially given their large cross border client base and Uruguay’s increase

Horizon Petroleum Enters into Definitive Agreements to Acquire Concessions in Poland19.9.2017 16:05Tiedote

Horizon Petroleum Ltd. (the “Company” or “Horizon”) (TSXV:HPL) is pleased to report that further to its press releases dated June 23, 2017, and July 26, 2017, it has entered into a series of definitive agreements (the “Agreements”) with Dublin-based San Leon Energy plc (“SLE”) regarding the purchase from wholly-owned subsidiaries of SLE and other SLE-controlled entities, of 100% interests in 2 oil & gas concessions in the Republic of Poland known as Cieszyn and Bielsko-Biala (the “Primary Concessions”), plus 100% working interests in 2 additional oil & gas concessions in Poland known as Prusice and Kotlarka, and another concession which is under application (together the “Secondary Concessions”). These concessions cover 3,030km2 and lie within the prolific Rotliegendes Basin and Carpathian Foldbelt, where Horizon intends to target undeveloped conventional natural gas discoveries. Gas infr

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme